Fluvastatin EP Impurity E
It is an impurity present in Fluvastatin, Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A reductase, HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol, the result is decreased levels of plasma total and LDL cholesterol. which is used to lower lipid levels and reduce the risk of cardiovascular disease.
Additional information on Fluvastatin EP Impurity E
VE009840
N/A
C24H22FNO3
391.4 g/mol
Fluvastatin
(6R)-6-[(E)-2-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]ethenyl]-4-hydroxy-5, 6-dihydro-2H-pyran-2-one
N/A
Adams, S. P., Sekhon, S. S., Tsang, M., & Wright, J. M. (2018). Fluvastatin for lowering lipids. Cochrane Database of Systematic Reviews, 2018(3). https://doi.org/10.1002/14651858.cd012282.pub2
In-stock
